<DOC>
	<DOCNO>NCT01160926</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) AZD6244 AZD2171 combine pre-operative capecitabine radiotherapy patient locally advanced rectal cancer .</brief_summary>
	<brief_title>Dual REctcal Angiogenesis MEK Inhibition radioTHERAPY Trial</brief_title>
	<detailed_description>The best curative resection rate report patient operable rectal cancer treat standard chemoradiotherapy approximately 50-60 % .The pathological complete response rate 10-20 % . Therefore , need effective treatment . In trial evaluate combination chemoradiotherapy either VEGFR ( vascular endothelial growth factor receptor ) MEK ( MAP Kinase ) inhibitor . Aims 1 . Define tolerability , MTD ( maximum tolerate dose ) DLT ( dose limit toxicity ) chemoradiotherapy combination - cediranib , VEGF receptor tyrosine kinase inhibitor inhibit angiogenesis - AZD6244 , potent MEK inhibitor inhibits cell proliferation 2 . Define dose suitable phase II evaluation 3 . Test impact combination soluble imaging ( FLT-PET DCEMRI/DWI ) biomarkers guide use phase II test Summary Patients receive standard chemoradiotherapy plus ascend dos AZD6244 cediranib day -10 ( relative start chemoradiotherapy ) day 35 . If feasible , patient ' tumour resect 10-12 week treatment . Translational study available tissue blood perform DCE-MRI/DWI FLT-PET carry 5 patient expand cohort AZD6244 ( FLT-PET DCE-MRI ) 5 patient expand cohort cediranib ( DCE-MRI ) . Cohorts Cediranib - 15mg od , 20mg od 30mg od AZD6244 - 50mg bd 75mg bd</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Inc Criteria : Histologically confirm rectal adenocarcinoma MRI ( magnetic resonance imaging ) triphasic CT ( computerise tomography ) define locally advanced rectal cancer : Mesorectal fascia involve Mesorectal fascia threaten Any T3 tumours &lt; 5cm anal verge Primary resection unlikely achieve clear margin No previous chemotherapy radiotherapy rectal cancer Bone marrow function : absolute neutrophil count ≥1.5 x109/l platelet count &gt; 100 x109/l Hepatobiliary function : serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) ; serum ALP &lt; 5 x ULN ; serum transaminase ( AST ALT ) &lt; 2.5 x ULN Renal function : Serum creatinine clearance &gt; 50mL/min either CockcroftGault formula EDTA ( ethylenediaminetetraacetic acid ) clearance ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) 01 Disease encompass within radical radiotherapy treatment volume No preexisting condition would deter radiotherapy , e.g . fistula , severe ulcerative colitis , Crohn 's disease , prior adhesion For woman childbearing potential negative pregnancy test require adequate contraceptive precaution condom partner must use . For men adequate contraception must use . Fit receive study treatment Able comply oral medication protocol Signed , write date informed consent . Life expectancy ≥ 3 month . Exc Criteria : Concurrent uncontrolled medical illness , previous/current malignant disease likely interfere protocol treatment Age &lt; 18 Any pregnant , lactate woman potentially childbearing patient use adequate contraception Previous chemotherapy radiotherapy rectal cancer Metastatic disease ECOG PS &gt; 1 Patients significant small bowel delineate within radiation field . Current impend rectal obstruction ( unless defunctioning stoma present ) , metallic colonic rectal stent situ Pelvic sepsis . Uncontrolled cardiac , respiratory disease , serious medical psychiatric disorder would preclude trial therapy inform consent . Cardiac condition follow : Uncontrolled hypertension ( rest BP ≥150/95mmHg despite optimal therapy ) Heart failure NYHA Class II Prior current cardiomyopathy Atrial fibrillation heart rate &gt; 100 bpm Unstable ischaemic heart disease Refractory nausea vomiting , chronic gastrointestinal disease , significant bowel resection would preclude adequate absorption trial drug Patients deem unsuitable surgery comorbidity coagulation problem . Recent ( &lt; 14 day ) major thoracic abdominal surgery prior entry study surgical incision fully heal would prevent administration study treatment Known DPD ( dihydropyrimidine dehydrogenase ) deficiency Patients suffer condition may affect absorption capecitabine IMP ( investigational medical product ) Any evidence severe uncontrolled systemic disease , active infection , active bleeding diatheses renal transplant , include patient know Hep B , Hep C HIV Mean QTc Bazetts correction &gt; 470msec screen ECG history familial long QT syndrome EXC CRITERIA ( AZD6244 cohort ) KRAS ( Kirsten ras sarcoma viral oncogene ) wildtype Prior treatment MEK inhibitor Baseline LVEF ( leave ventricular ejection fraction ) ≤50 % EXC CRITERIA ( Cediranib cohort ) Known hypersensitivity Cediranib excipients Greater +1 proteinuria two consecutive dipstick take less 1 week apart unless urinary protein &lt; 1.5g 24 hr period protein/creatinine ratio &lt; 1.5 . Significant haemorrhage ( &gt; 30mL bleeding/episode previous 3 month ) haemoptysis ( &gt; 5mL fresh blood previous 4 week ) APTT ratio &gt; 1.5 x ULN Arterial thromboembolic event ( include ischemic attack ) previous 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>AZD6244</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>AZD2171</keyword>
	<keyword>Cediranib</keyword>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>FLT-PET ( fluoro-l-pyrimidine positron emission tomography )</keyword>
	<keyword>DCE-MRI ( dynamic contrast enhance magnetic resonance imaging )</keyword>
</DOC>